Chronic Lymphocytic Leukemia
In patients with treatment-naive CLL, Venetoclax Plus Obinutuzumab Shows Durable Survival Benefits
SG Tylor
According to 6-year results from the Phase III CLL14 trial (NCT02242942), fixed-duration venetoclax (Venclexta) plus obinutuzumab (Gazyva) therapy resulted in ...
ASCO 2023: BREYANZI Shines as First CAR T Therapy with Deep and Lasting Impact in Chronic Lymphocytic Leukemia
SG Tylor
The initial findings from the important TRANSCEND CLL 004 study, which is evaluating the use of BREYANZI (lisocabtagene maraleucel) in ...
